Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Current Opinion in Hematology|January 7, 2020
Relapsed or primary refractory AML: moving past MEC and FLAG-idaKristin Koenig, Alice Mims
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
The Changing Landscape of Treatment in Acute Myeloid LeukemiaKristin Koenig, Alice Mims, Mark J Levis, et al.
Current Hematologic Malignancy Reports|May 4, 2013
Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Alice Mims, Robert K Stuart
Molecular Pharmacology|January 26, 2006
Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrixYoko Otake, Alice Mims, Daniel J Fernandes
Frontiers in Oncology|October 20, 2022
Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapyKieran Sahasrabudhe, Ying Huang, Melanie Rebechi, et al.
Leukemia & Lymphoma|November 28, 2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemiaAlice Mims, Zhuoer Xie, Ravi Potluri, et al.
Cancer Medicine|April 15, 2018
Incidence and survival of hematological cancers among adults ages ≥75 yearsJessica L Krok-Schoen, James L Fisher, Julie A Stephens, et al.
Leukemia & Lymphoma|October 12, 2024
Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapiesJean Caputo, Ayush Peddireddi, Subodh Bhatta, et al.
The Oncologist|August 12, 2025
Barriers and Facilitators to Representative Acute Leukemia Trial Participation at National Cancer Institute-Designated Comprehensive Cancer CentersAndrew Hantel, Eric C Blackstone, Anna C Revette, et al.
Blood|April 21, 2012
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaJosephine Aimiuwu, Hongyan Wang, Ping Chen, et al.
Pageof 5